Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBX-102-02 microbiota capsule trial for IBS-C
ISRCTN15681288Phase 2Recruiting
- Sponsor
- EnteroBiotix
- Start
- May 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of EBX-102-02 in irritable bowel syndrome (IBS) (3 arms), sponsored by EnteroBiotix. Started May 2026; status: recruiting.
02
Drugs
EBX-102-02
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ISRCTN15681288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15681288.